# Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease

> **NCT02843165** · PHASE2 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 106 (actual)

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** Checkpoint blockade immunotherapy
- **RADIATION:** Checkpoint blockade immunotherapy plus SBRT

## Key facts

- **NCT ID:** NCT02843165
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-02
- **Primary completion:** 2021-08-16
- **Final completion:** 2024-08-15
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02843165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02843165, "Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02843165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*